#United States #Waltham #Q32 Bio #Bempikibart #Alopecia Areata

Q32 Bio Announces Large Public Offering for Innovative Therapies

WALTHAM, Mass., July 13, 2026 – In a strategic move to bolster its financial standing and expedite the development of its innovative treatments, Q32 Bio Inc. (Nasdaq: QTTB), a clinical-stage biotechnology firm, has announced a public offering aimed at raising $200 million. This significant capital inflow is intended to support Q32 Bio’s development of therapies primarily targeting alopecia areata (AA) as well as other autoimmune and inflammatory diseases.

Public Offering Details

The offering will include shares of common stock, and to accommodate certain investors, the company is also offering pre-funded warrants, allowing these investors to purchase common stock. In addition, Q32 Bio plans to provide the underwriters a 30-day option to acquire up to $30 million in additional shares under the same terms suggested for the initial offering.

Morgan Stanley, Jefferies, and Cantor Fitzgerald are leading this initiative as joint book-running managers, with Oppenheimer Co. also playing a pivotal role in the offering.

Usage of Proceeds

The net proceeds from this offering are earmarked for various working capital uses. These include funding ongoing research, advancing clinical development, and facilitating commercialization efforts, notably in support of the clinical trials for bempikibart, Q32 Bio’s leading candidate for alopecia areata treatment. This drug is currently undergoing a Phase 2 clinical trial with promising initial results.

Market Conditions and Future Expectations

While the company is optimistic about the offering, it is important to note that the success of this public offering is contingent upon market conditions and other factors, which introduces an element of uncertainty regarding the final outcome and terms of the offering. Q32 Bio emphasizes that no guarantees can be made about whether the offering will be completed as planned.

Regulatory Compliance

The securities associated with this offering will be made available under an effective shelf registration statement filed with the Securities and Exchange Commission (SEC). Potential investors will be able to access preliminary prospectus information through the SEC website or through the affiliated book-running managers.

Company Background

Founded with a vision to transform the treatment of autoimmune disorders, Q32 Bio remains committed to addressing complex medical conditions impacting hundreds of thousands of individuals. Approximately 700,000 Americans live with alopecia areata—a condition that drastically alters patients' lives, significantly impacting their emotional and psychological well-being, with limited effective treatment options currently available.

Q32 Bio’s ongoing clinical efforts specifically target the mechanisms underlying these autoimmune responses. Its lead therapeutic, bempikibart, is a fully human anti-IL-7Rα antibody designed to re-regulate adaptive immune function. Through continuous research and clinical trials, the company aims to deliver innovative solutions not only for alopecia areata but also for various other related disorders.

Forward-Looking Statements

It is crucial for potential investors to note that this announcement contains forward-looking statements as defined under the Private Securities Litigation Reform Act. These statements involve risks and uncertainties, particularly regarding the timing and execution of the proposed public offering, the use of proceeds, and the successful development of its drug candidates. Actual results may differ significantly from these projections due to various factors, including clinical trial outcomes and financial market conditions.

As Q32 Bio traverses this challenging yet potentially rewarding landscape, the biotechnology sector watches closely what outcomes this public offering will yield for both the company and the broader community affected by these conditions.

For ongoing updates and detailed information, interested parties can follow Q32 Bio’s announcements or visit their official website for resources on the company’s health innovations and financial engagements.